AeroVironment (AVAV) Q3 FY2026 Post-Earnings Debrief

1. Executive Summary

• Revenue of $408M missed the $561M consensus by 27%, driven by SCAR contract termination, government shutdown timing delays, and $40M of high-margin revenue slipping to Q4 — making this one of the largest top-line misses in the company's history as a public entity.
• Adjusted EPS of $0.64 fell 63% below the $1.74 consensus, reflecting both the revenue shortfall and continued gross margin compression at 27%, down from 40% in the year-ago period and well below management's prior Q4 target of "high-30s."
• The US Space Force terminated the SCAR/BADGER contract for convenience, triggering a $151M goodwill impairment and the unwinding of ~$1.5B in SCAR-related unfunded backlog — the single largest negative event since the BlueHalo acquisition closed in August 2024.
• Management cut FY2026 guidance across all key metrics, with the EPS midpoint of $2.93 sitting 11.5% below the prior Street consensus of $3.31 and the revenue midpoint of $1.90B implying 3.6% downside to the $1.97B estimate.
• Funded backlog reached a record $1.1B (+51% YoY) and year-to-date awards totaled $4.6B, including an $874M sole-source FMS IDIQ, $168M Switchblade task order, and $23M Titan USMC order — suggesting the core Autonomous Systems franchise remains healthy despite the SCAR headwind.
• The Autonomous Systems segment delivered $279M (+25% pro forma), with legacy AV organic revenue growing 38% YoY and UAS ex-Ukraine surging 54%, while Space, Cyber & Directed Energy contracted 19% pro forma on the SCAR-driven disruption.
• CEO Nawabi characterized demand as "unprecedented" and the Iran conflict as a "once-in-a-generation opportunity," projecting Titan counter-UAS production to scale 4x this year and 10x by FY2030, with the Salt Lake City 140K sqft manufacturing facility approximately one year from operational.
• CFO Kevin McDonnell announced his retirement effective end of July 2026 — a leadership transition that adds execution uncertainty during a period of acquisition integration, guidance resets, and the SCAR recompete process.
• The stock has declined 48% from its January 16 high of $393 to the $203 after-hours level, with the March 2 SCAR-related crash (-17.4% on 13.5M shares, 5.4x average volume) and tonight's -8.4% after-hours move representing the two largest single-event drawdowns in the period.
• The bull/bear debate now centers on whether the record backlog, Iran-driven demand acceleration, and Switchblade/Titan production ramps can offset the SCAR loss, persistent margin compression, and eroding Street credibility — with forward valuation at ~69x the FY2026 EPS midpoint and ~51x the FY2027 consensus of $4.00.

2. What Actually Mattered

3. Results Versus Expectations

The magnitude of the miss is historically significant. Revenue fell 27% below consensus — a level of underperformance typically associated with structural business model issues rather than timing delays. The EPS miss of 63% reflects both the revenue shortfall and margin compression. Management attributes a meaningful portion to government shutdown timing and $40M of supply chain-driven revenue push to Q4, but the SCAR termination accounts for the structural portion of the gap.

4. Historical Quarterly Comparison

Note: Quarters prior to Q1 FY2026 are pre-BlueHalo acquisition (closed Aug 2024). Pro forma comparisons are approximate.

Three consecutive quarterly revenue misses since Q1 FY2026 — the first full quarter with BlueHalo. The combined entity has not delivered a clean beat since the acquisition. Gross margins have compressed from 40% (Q3 FY25 legacy AV) to a persistent 26-27% range, reflecting BlueHalo's lower-margin cost-plus contract mix and integration costs. EBITDA margin has improved sequentially (9% → 10% → 11%) but remains far below pre-acquisition operating leverage.

5. Guidance Bridge and Implications

FY2026 Guidance: Prior vs. Revised

Implied Q4 FY2026

Nine-month revenue of ~$1.3B implies Q4 needs $550-650M to reach the $1.85-1.95B full-year range. This would be a record quarter by a wide margin (prior record ~$505M in Q2 FY26). Management claims 98% visibility to the midpoint and expects record Q4 revenue. The $40M of high-margin revenue pushed from Q3 to Q4 supports this claim directionally. The implied Q4 EBITDA of $138-158M (to reach full-year $265-285M) would require a step-function improvement to 22-25% EBITDA margins — a significant acceleration from the 9-11% range of the first three quarters. This is the critical prove-it quarter.

Guidance Bridge Decomposition

The $100-50M revenue cut maps roughly to: (1) SCAR termination impact on Q3 actual and Q4 run-rate (~$50-75M), (2) government shutdown timing delays on order flow (~$25-40M partially recoverable), and (3) the $40M revenue push from Q3 to Q4 (neutral to full-year but negative to Q3). The EPS cut is more severe than the revenue cut suggests, reflecting margin compression — the lost SCAR revenue was transitioning to higher-margin firm-fixed-price work, and its removal disproportionately impacts earnings leverage.

6. Estimate Revision Implications

The current Street consensus was built on the assumption that BlueHalo integration would drive margin expansion and SCAR would contribute meaningfully to FY27-28 revenue. Both assumptions are now impaired. FY2027 consensus EPS of $4.36 is materially too high — SCAR revenue of less than $100M in FY27 (per management disclosure to DiPalma on the call) versus the embedded assumption of $200-300M+ represents a direct $0.40-0.80 EPS headwind before accounting for the delayed margin expansion timeline. Expect 15-19 analyst notes within 48-72 hours, with the majority cutting both price targets and EPS estimates. Goldman ($429 PT), Needham ($450 PT), and BNP ($425 PT) face the largest required adjustments.

7. Transcript Intelligence

Prepared Remarks Tone

Q2 (Dec 9, 2025): Triumphant and expansive. CEO Nawabi opened with superlatives — "excellent quarter," "setting new records," "historic record achievement." He spent extensive time on product launches (Switchblade variants, VAPOR CLE, AV_Halo modules), international expansion, and described SCAR/BADGER as a "tremendous growth opportunity." The tone was almost celebratory, with phrases like "setting the pace for everyone else to follow."

Q3 (Mar 10, 2026): Defensive, damage-control, accountability-signaling. The pivot was immediate: "This past quarter's results came in below expectations, primarily driven by revenue timing and adjustments made in our space business." Within 90 seconds, Nawabi deployed three compensatory frames: (1) blame external factors (government shutdown), (2) acknowledge the miss ("Recognizing we fell short"), and (3) pivot to forward strength ("more than ever focused on leveraging our unique capabilities"). The SCAR section consumed disproportionate prepared remarks time — a sharp reversal from Q2's brief, optimistic mention. Nawabi used the word "recipe" three times to describe the commercialization playbook and invoked "several times in our history" twice, suggesting a management team reaching for historical precedent to buttress a weakened position.

CFO McDonnell was notably somber in Q3, leading with "While the third quarter did not meet our expectations on several fronts" — unusual for a CFO who typically leads with positives. His farewell remarks referenced growing the company "from $1 billion to over $10 billion" in market cap and included the revealing phrase "there's nothing to be ashamed about this" — candid acknowledgment that the Street reaction would be harsh.

Q&A Intelligence

Best analyst questions (ranked):

• Louie DiPalma (William Blair) — Most effective on the call. Extracted the critical SCAR FY27 quantification ("less than $100 million"), probed LASSO competitive dynamics (noting four competitors had made recent announcements), and connected Iran conflict to Freedom Eagle timeline. Three questions, three pieces of actionable intelligence.
• Trevor Walsh (Citizens JMP) — Distinguished between cosmetic business-model relabeling and genuine technology risk in the SCDE commercial pivot, then extracted McDonnell's candid admission on capacity constraints and margin compression. High signal.
• Jonathan Siegmann (Stifel) — Best conceptual question on SCAR: "What does success look like in the re-compete?" Forced the FY28 timeline disclosure for significant Badger revenue.

Management deflected or was vague on: Specific autonomous segment revenue breakdown, precise SCAR FY26 revenue, EBITDA bridge components, Switchblade capacity by variant, FY27 guidance framework, and free cash flow specifics. No analyst pressed on the $40M revenue push mechanics, CFO search process, unbilled receivables trajectory, or the $0.5B LOCUST Golden Dome claim.

Q&A quality rating: 6.5/10. Key intelligence was extracted on SCAR (<$100M FY27, FY28 for Badger revenue, 80-90% tile reusability), but the $40M revenue push — representing 10% of Q3 revenue — received zero follow-up. Nobody challenged the "3-3.5 year head start" claim or asked about CFO succession.

Cross-Quarter Language: Q2 → Q3

Management Quotes by Theme

SCAR/Space — Damage Control:

"As of this morning, we could not come to a mutually acceptable agreement with our customer to modify the existing contract and resume work. Therefore, the US Space Force has concluded to terminate our existing contract for convenience." — CEO Nawabi

"We believe we have at least a three to three and a half year head start on all competitors." — CEO Nawabi

"Space Force has directly told me that they're actually going to invest more money in this area because we need it as a country." — CEO Nawabi

Demand Environment:

"The demand for cost-efficient, AI-enabled, autonomous, non-lethal, and lethal drones and counter drones are unprecedented." — CEO Nawabi

"The fundamental underlying demand for our systems has never been stronger in my tenure at AV for 16 years." — CEO Nawabi

"I just read a press release or report this week that Iran has launched close to 1,400 one-way attack drones into UAE alone in one week." — CEO Nawabi

Margin/Revenue Pressure:

"Third quarter margins were also affected by a last minute shipping and supply chain issues resulting in a $40 million of high margin revenue push to Q4." — CFO McDonnell

"There's nothing wrong with this year... $1.9 billion of revenue, putting these two companies together and facing all those challenges... I'm very proud of that." — CFO McDonnell

Manufacturing Scale:

"We are actively increasing manufacturing by more than four times this year, with additional plans to increase by more than 10 times current levels by fiscal year 2030." — CEO Nawabi (on Titan counter-UAS)

"We can't make those fast enough. We are ramping production as fast as humanly possible while keeping the quality high." — CEO Nawabi

Forward Outlook:

"We expect to achieve higher gross margins next year than this year, which will drive accelerate or continue EBITDA growth probably greater than revenue next year." — CFO McDonnell (on FY27)

"I expect all this to convert to some additional demand in fiscal year 27 and beyond." — CEO Nawabi (on Iran conflict demand)

8. Segment and KPI Forensic Review

Segment Performance

Key KPIs

Forensic Assessment: The two-segment story is increasingly clear. Autonomous Systems is executing — organic growth of 38%, order flow accelerating on Iran-driven demand, production scaling on multiple platforms. SCDE is impaired — SCAR termination removes the growth catalyst, cyber/mission systems declined 22% on timing, and the $151M goodwill impairment formally marks down the acquisition economics. The concern is that SCDE represents 32% of revenue and its trajectory is uncertain absent SCAR. Investors need to model SCDE as a flat-to-declining segment through FY27 while the recompete plays out.

9. Quality of the Quarter

Revenue Quality: LOW. The 27% miss makes the headline number unreliable as a baseline. The $40M revenue push to Q4 ("last minute shipping and supply chain issues") is an unverified claim that could represent either genuine logistics delays or revenue management. Three of four quarters missed post-BlueHalo — the pattern suggests systematic over-estimation of revenue timing in the combined entity, not bad luck.

Margin Quality: LOW. Adjusted gross margin of 27% is flat with Q2 but 1,300bp below the year-ago quarter. The Q4 target has been progressively walked down from "high-30s" (Q2 call) to "low-to-mid 30s" (Q3 call). Full-year gross margin was softened from "low-30s" to "high 20s, low 30s." The margin compression is structural: BlueHalo's cost-plus contracts run at lower margins than legacy AV's commercial/FMS business, and the SCAR removal eliminates the program that was supposed to drive the margin mix-shift.

EPS Quality: LOW. The $0.64 adjusted EPS excluded the $151M goodwill impairment and other one-time charges. GAAP was $(3.15). Even on an adjusted basis, the 63% miss to consensus reflects both top-line shortfall and margin pressure. The sequential improvement from $0.38 (Q2) to $0.64 (Q3) is positive but insufficient to bridge the full-year gap.

Cash Flow Quality: UNCLEAR. Management did not provide detailed free cash flow figures. Unbilled receivables "continue to be at a higher level than we are targeting" per McDonnell, suggesting working capital remains a drag. The "significant collection activity at the end of the quarter" comment implies a push to convert receivables but the outcome was apparently insufficient.

Backlog Quality: MIXED. Funded backlog of $1.1B is a record and provides genuine visibility. However, the flat sequential trend (also $1.1B in Q2) and the pending $1.5B SCAR unfunded backlog unwind will produce an optically alarming headline in Q4. The 1.6x book-to-bill on YTD orders of $4.6B is genuinely strong, but ceiling-value IDIQs (like the $874M FMS contract) overstate near-term revenue conversion rates.

One-Time Items: $151M goodwill impairment (non-cash, SCAR-related), SCAR termination (non-recurring but with ongoing revenue impact), $40M revenue push (timing — should reverse in Q4). Stripping these out, the "underlying" quarter still missed on both revenue and margins, suggesting the issues extend beyond SCAR.

10. Options and Volatility Diagnostics

Stock Performance vs. Benchmarks

Key Read: The P/C ratio of 0.71 (more calls than puts) confirms the options market was positioned for upside heading into the print, likely driven by the Iran conflict narrative and the 9.6% pre-earnings rally. Straddle buyers near the ±10% implied move were roughly at breakeven. The 30D realized vol of 100% is extraordinary for any name, let alone a mid-cap defense stock — this level of volatility typically indicates either a restructuring situation or an unresolved binary event. AVAV now has both. Technical positioning is severely damaged: the stock trades 21% below its 50-DMA ($281) and 19% below the 200-DMA ($274), with RSI at 40.9 approaching oversold territory.

11. Stock Reaction Drivers

The -8.38% after-hours decline to $203.01 was driven by three compounding factors, none of which were fully priced despite the SCAR-related selloff earlier in the month:

Primary Driver: Revenue Miss Magnitude (-27% vs. consensus). Even after adjusting expectations lower post-SCAR, the Street did not anticipate a $153M revenue shortfall. The miss extends beyond SCAR to government shutdown timing and the undisclosed $40M supply chain push — suggesting the forecasting problem is broader than the Space segment alone. This is the third miss in four quarters, establishing a credibility pattern that will weigh on the multiple.

Secondary Driver: Guidance Cut — EPS Midpoint 11.5% Below Street. The FY2026 EPS range of $2.75-3.10 (midpoint $2.93) versus the $3.31 consensus forces immediate estimate revisions. More importantly, the walkdown in Q4 gross margin targets from "high-30s" to "low-to-mid 30s" removes the margin inflection point that bulls were using to model FY27 acceleration.

Tertiary Driver: SCAR Resolution Confirmed Negative. While the termination was partially known from March 2-3 news flow (which drove the -17.4% crash on 13.5M shares), tonight's call provided three incremental negatives: (1) the $151M goodwill impairment, formally marking down the acquisition economics; (2) the FY28 timeline for meaningful Badger revenue recompete — later than many bulls assumed; and (3) the $1.5B unfunded backlog unwind, which will produce a jarring headline when reported in Q4.

Context: The March 2 SCAR crash (-17.4%) was the more violent event. The 13.5M shares traded that day (5.4x average volume) represented genuine institutional capitulation on the SCAR thesis. Tonight's -8.4% move is incrementally negative but within the range of normal post-earnings reactions. The cumulative damage — $393 to $203, a 48% decline in less than two months — is the more important figure for positioning analysis. From the November 3 period high of $368, the stock has lost 45% of its value.

What was NOT a reaction driver: The Iran conflict demand narrative was well-understood pre-print and bullish commentary on the call did not offset the quantitative miss. The CFO retirement was incrementally negative but not a primary mover. The goodwill impairment is non-cash and largely mechanical — it formalizes what the stock price already reflected.

12. What Mattered Less Than It Appeared

• $151M Goodwill Impairment: Large headline number but non-cash. Represents a 17% write-down of the acquired space business value. The market already priced in the SCAR loss through the March 2 crash — this is accounting catching up to market reality, not new information.
• +143% YoY Revenue Growth (As Reported): Entirely an artifact of the BlueHalo acquisition. Pro forma growth was +6%. Reporting this headline figure without the pro forma context would be misleading.
• "Record" Funded Backlog: At $1.1B, funded backlog is at a record — but it was also $1.1B at Q2. Flat sequential backlog with record awards suggests conversion/burn-down is accelerating, which is positive for near-term revenue but means the "record" label is doing more narrative work than analytical work.
• $4.6B YTD Awards: Impressive on its face, but heavily weighted by ceiling-value IDIQs (e.g., $874M FMS contract) where actual task order flow may be a fraction of the ceiling over the contract period. Awards ≠ funded orders ≠ near-term revenue.
• "98% Visibility to Midpoint": Higher than Q2's 93%, but the midpoint itself was cut by ~$70M on revenue and ~$0.55 on EPS. Having higher visibility to a lower number is not bullish — it simply confirms the reduced trajectory.
• Iran Conflict Commentary: Nawabi's characterization of Iran demand as a "once-in-a-generation opportunity" is directionally correct but temporally disconnected from Q3 results. The conflict's revenue impact is largely FY27+, and the conversion rate from geopolitical demand signals to funded orders to delivered revenue involves multiple lags. The market knows this.
• Blue Halo Integration "On Track": Management's claim that year-one synergies have been "largely achieved" may be technically accurate, but the gross margin trajectory (40% → 27% and stuck) and consecutive quarterly misses tell a more nuanced story.

13. Post-Print Analyst Activity

Earnings were reported after market close on March 10. As of this report, no post-Q3 analyst notes have been published. The table below reflects the most recent pre-earnings positioning:

Current Consensus: 19 analysts — 15 Buy/Outperform, 2 Neutral/Hold, 2 Underperform/Underweight. Mean PT $363, median $365 — implying +64% upside from close, +79% from after-hours. These targets are overwhelmingly stale.

Expected Post-Q3 Activity (next 48-72 hours):

• Most exposed to cuts: Goldman ($429), Needham ($450), BNP ($425), BTIG ($415) — all carry targets 100%+ above the AH price. Expect 20-35% PT reductions.
• Already adjusted pre-Q3: Baird ($260) and RBC ($325) cut on SCAR news. Baird is closest to current trading levels and may hold. RBC likely cuts further.
• Raymond James (Underperform): Only sell-side bear — downgraded on March 2 SCAR news. Likely vindicated by the print. Watch for others to move toward caution.
• Downgrade risk: Medium probability of 1-2 additional downgrades to Neutral/Hold from firms with the most aggressive targets. UBS ($259, Neutral) is already closest to fair value territory.
• Notable absence: Goldman Sachs did not participate in the Q3 call. Their next action will be closely watched given the $429 PT.

14. Peer and Sector Read-Through

Sector Read-Through:

• Iran Conflict — Broadly Positive for Defense: Operation Epic Fury (commenced Feb 28) is driving sustained demand for munitions, interceptors, and drone systems across the sector. RTX, LMT, and NOC have all been trending higher on conflict demand. AVAV's miss is idiosyncratic, not a sector signal.
• Drone Market Competitive Fragmentation: The Pentagon's Drone Dominance Program ("Gauntlet") has 25+ vendors in Phase 1, including KTOS, Anduril, Shield AI, and Red Cat. The market is moving from sole-source relationships toward competitive procurement. AVAV retains an incumbent advantage (Switchblade brand recognition, production scale, $990M IDIQ) but the competitive moat is narrowing.
• SCAR is AVAV-Specific: The Space Force's move to competitive bidding for satellite ground terminal work (BADGER) reflects a broader Pentagon shift away from cost-plus toward commercial procurement, but the $151M impairment and $1.5B backlog unwind are entirely AVAV/BlueHalo-specific. No peer-read-through for primes on this particular contract loss.
• Valuation Divergence: At ~69x FY2026E and ~51x FY2027E, AVAV trades at 3x the forward multiple of traditional primes (LMT, RTX, NOC at 17-20x). This premium requires demonstrated growth execution — and three consecutive misses make that premium increasingly difficult to justify. KTOS trades at a comparable premium (~55x) on similar growth expectations, providing the closest valuation comp.
• Counter-UAS TAM Validation: The Iran conflict validates the counter-UAS thesis that underpins AVAV's Titan and Freedom Eagle programs. The Army's stated plan to purchase 1M+ drones over 2-3 years, combined with $25B in budget reconciliation munitions funding, suggests the TAM expansion is real — even if AVAV's share is debatable.

15. Investment Implications

Near-Term (1-5 Trading Days)

Expect a -8% to -12% open on March 11, with the after-hours -8.4% as the starting point. Analyst notes will arrive throughout March 11-12, with the majority cutting price targets 20-35%. The narrative will center on the revenue miss magnitude, guidance cut, and SCAR finality. Potential support at the March 2 SCAR crash low of $208 — if $203 AH holds, the stock may find a base in the $195-210 range. Volume will be elevated (2-3x average) as institutional holders reassess position sizing. Short-term bounce risk exists if Q4 record revenue narrative gains traction in analyst notes, but the base case is continued pressure through the week.

Next Quarter (Q4 FY2026)

Q4 is the critical prove-it quarter. Management needs to deliver: (1) revenue of $550-650M (record), (2) gross margins in the "low-to-mid 30s," and (3) EBITDA that bridges to the $265-285M full-year range. The 98% visibility claim and $40M revenue push from Q3 provide some support. However, the implied Q4 EBITDA margin of 22-25% represents a step-function improvement from the 9-11% range of Q1-Q3. Any execution shortfall in Q4 would represent a fourth consecutive miss and likely trigger downgrades across the coverage universe. Earnings expected late May/early June 2026.

Next 6-12 Months

The investment thesis shifts from "SCAR optionality + BlueHalo integration" to "Autonomous Systems organic growth + Iran-driven demand cycle." FY2027 becomes the first clean year for the combined entity, with SCAR contributing less than $100M and management guiding to "EBITDA growth greater than revenue growth." Key variables: (1) Switchblade production ramp to 1,200 units/month, (2) Titan 4x production increase, (3) Salt Lake City facility operational (summer 2027), (4) LASSO competitive outcome, (5) new CFO quality, (6) FY27 guidance credibility. If management delivers Q4 and sets a credible FY27 framework, the stock can re-rate toward $250-280 on a 40-45x FY27 EPS. If Q4 misses or FY27 guidance disappoints, the stock could test $160-180 as the premium collapses.

Bull vs. Bear Post-Print

16. What to Watch Next

17. Appendix

Senior Executives on Call

• Wahid Nawabi — Chairman, President & Chief Executive Officer
• Kevin McDonnell — Senior Vice President & Chief Financial Officer (retiring end of July 2026)

Sell-Side Analysts on Call — Q3 FY2026

Notable Q2 analysts absent from Q3 call: Goldman Sachs (Anthony Valentini), Cantor Fitzgerald (Colin Canfield), Jefferies (Greg Konrad), Alembic Global (Pete Skibitski). Goldman's absence from a miss quarter is particularly notable given their $429 price target — the highest on the Street.